checkAd

     109  0 Kommentare Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

    Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in Boston, April 5-8, 2024.

    Podium presentations include the results of studies evaluating the new TENEO Excimer Laser Platform, enVista and IC-8 Apthera intraocular lenses (IOLs) and MIEBO. MIEBO is indicated for the treatment of the signs and symptoms of dry eye disease. Poster presentations include the results of TENEO and IC-8 Apthera IOL studies.

    In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

    Bausch + Lomb activities at ASCRS:

    Podium Presentations

    • “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
    • “Binocularity and Stereoacuity in Modern Monovision with a Small-Aperture IOL.” Wiley et al.
    • “Characterization of Discontinuation and Switching Patterns of Dry Eye Disease Medications Using Linked EHR Registry and Claims Data.” Mbagwu et al.
    • “Clinical Results of Small-Aperture IOL Implantation Following Corneal Inlay Removal.” Ang et al.
    • “Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens*: A Prospective, Multicenter Canadian Study.” Muzychuk et al.
    • “Early Real World Outcomes of Small Aperture IOL in Post Refractive Eyes.” Hu et al.
    • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
    • “Patient-Reported Instillation Comfort and Eyedrop Acceptability of Perfluorohexyloctane Ophthalmic Solution in Pivotal Clinical Studies.” White et al.
    • “Patient-Reported Outcomes Following LASIK, Performed Using a Novel Excimer Laser for the Correction of Myopia and Myopic Astigmatism.” Stonecipher et al.
    • “Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease: Efficacy Among Various Participant Subgroups in Pivotal Clinical Trials.” Sheppard et al.
    • “Predicted In-Vitro versus In-vivo Measurements of Higher-Order Corneal Aberrations following Apthera Implantation Post Radial Keratotomy.” Devaro et al.
    • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.
    • “Subjective versus Objective Depth of Focus from Ray-Tracing Aberrometry in Small Aperture Optics Intraocular Lens in Eyes with Aberrated Corneas.” Barros et al.
    • “Visual and Refractive Outcomes following Bilateral Implantation of a Novel Trifocal* or Monofocal IOL: A Prospective, Multicenter US study.” Liang et al.
    • “Visual Performance of Negative versus Neutral Aspheric Monofocal Intraocular Lenses: A Randomized Controlled Trial.” Kudrna et al.

    Poster Presentations

    Seite 1 von 6



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer